Hypertension is a major risk factor for cardiovascular morbidity and mortality. Effective control of elevated blood pressure (BP) has been shown to reduce this risk. Early studies of risk reduction assumed that the mechanism by which BP was lowered had little impact on the benefit obtained. Recent evidence, however, suggests that agents that inhibit the renin-angiotensin system may be particularly beneficial. The results of the recent Heart Outcomes Prevention Evaluation (HOPE) trial suggest that angiotensin-converting enzyme (ACE) inhibitors have a greater impact on cardiovascular morbidity and mortality than would be anticipated from their antihypertensive effects alone. Angiotensin receptor blockers, the other major class of antihypertensive drugs that inhibit the renin-angiotensin system, have not been widely tested in outcomes trials, but early results sug-
Introduction
Before the results of the Framingham Heart Study became available, there was little consensus regarding the pathophysiological importance of elevated blood pressure (BP), or the necessity for treatment of this condition, which was usually regarded as asymptomatic and benign. 1 As a result of subsequent extensive epidemiological research, hypertension is now recognised as a major risk factor for cardiovascular morbidity and mortality.
Data from the Framingham Heart Study reveal the magnitude of the risk imposed by hypertension.
2 Figure 1 shows results of 36 years of follow-up in subjects aged 35-64 years at enrolment. 2 In this study, hypertension was defined as a BP higher than 140/90 mm Hg. Men who are hypertensive by this definition are four-times more likely to experience a stroke or cardiac failure than normotensive control subjects. Among hypertensive women, the relative risk for these conditions is 3. Hypertension also doubles the risk of coronary heart disease in both genders. 2 Hypertension is generally defined as a systolic BP (SBP) higher than 140 mm Hg and/or a diastolic BP (DBP) higher than 90 mm Hg, but numerous studies have shown that the relationship between BP and cardiovascular disease is positive and continuous over a wide range of BPs. 3 For example, in the Multiple Risk Factor Intervention Trial (MRFIT), a study that followed almost 348 000 men at high risk for 11.6 years, the relative risk of death from coronary heart disease increased gradually from 1.0 in subjects with a baseline SBP lower than 112 mm Hg to 3.7 in subjects with a baseline SBP of at least 151 mm Hg. 4 The relationship between DBP and cardiovascular disease was similar. Using data from nine prospective observational studies that included 420 000 subjects, MacMahon and co-workers calculated that the risk of stroke and coronary heart disease increases gradually over a DBP range of 76-105 mm Hg. 3 The relative risk of stroke increased 10-to 12-times over this BP range. 3 These findings suggest that the risk ratios derived from the Framingham data should be regarded as conservative estimates when assessing a patient with a substantial elevation in BP. 
Treatment of hypertension reduces cardiovascular risk
Lowering BP is extremely effective in reducing the incidence of cardiovascular disease in hypertensive populations. Collins et al 5 reviewed the results of 14 unconfounded randomised trials involving 37 000 middle-aged hypertensive subjects who had a mean treatment duration of 5 years. They estimated that the average difference in DBP between the subjects allocated to antihypertensive treatment and those allocated to the control groups was 5-6 mm Hg. This difference was associated with reductions of 42% and 14% in the risks of stroke and coronary heart disease, respectively.
Antihypertensive treatment also has substantial benefits in elderly hypertensive patients, many of whom have isolated systolic hypertension. In the Systolic Hypertension in the Elderly Program (SHEP), 6 the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), 7 the Medical Research Council (MRC) trial of treatment of hypertension in older adults, 8 and the Systolic Hypertension in Europe (Syst-Eur) 9 trials, elderly hypertensive patients were randomized to active treatments or placebo. Active treatments were associated with a reduction of 25% in the risk of coronary artery disease, and with reductions of 25-47% in the risk of stroke. A recent review of the SHEP data showed that antihypertensive treatment reduced the risks of both haemorrhagic and ischaemic stroke. 10 In all trials, reductions in the overall incidence of cardiovascular endpoints ranged from 17 to 40%. [6] [7] [8] [9] Antihypertensive treatment is particularly beneficial among particular subgroups of the hypertensive population, such as patients with diabetes or nephropathy, who are at particularly high risk of cardiovascular complications. In the United Kingdom Prospective Diabetes Study (UKPDS), patients with type 2 diabetes were assigned to tight (Ͻ150/85 mm Hg) or less tight (Ͻ180/105 mm Hg) control of BP. 11 The mean BPs achieved in these two groups were 144/82 mm Hg and 154/87 mm Hg, respectively. Patients who were held to the more stringent BP goals experienced a significant reduction in the risk of stroke (44%) and cardiac failure (56%) compared with patients with the less tight goals. Diabetes-related end points were also reduced by 24% in the tight-control group compared with the group with less tight control, and diabetes-related deaths were reduced by 32%.
11
Among patients with nephropathy, lower mean arterial pressures are associated with slower declines in renal function. 12 Lazarus et al 13 showed that tight control of BP substantially reduces the risk of a cardiovascular event in patients with renal failure. Analysing data from 585 chronic renal failure patients, these authors found that each 1 mm Hg increase in SBP was associated with a 1.35-times greater risk of hospitalization for cardiovascular or cerebrovascular disease.
Despite the universally acknowledged benefit of BP control, overall management of hypertension is poor. Data from phase 2 of the National Health and Nutrition Examination Survey (NHANES) III show that effective BP control is achieved in only 27% of hypertensive subjects.
14 In the population of hypertensive adults, 32% are unaware of their condition and 41% are aware but are either untreated or uncontrolled despite treatment.
14 Although these disappointing statistics can be attributed partly to lack of aggressive management by physicians, 15 poor patient compliance is also a major factor. 16 Incon-venient dosing regimens and adverse events are both known to reduce compliance with antihypertensive therapy.
16,17

Comparative efficacy of antihypertensive drugs
Only a few trials have directly compared the efficacy of different classes of antihypertensive drug. In the Treatment of Mild Hypertension Study (TOMHS), 902 men and women with mild hypertension were randomized to treatment with a diuretic (chlorthalidone), a ␤-blocker (acebutolol), an ␣ 1 -antagonist (doxazosin), a calcium antagonist (amlodipine maleate), an angiotensin-converting enzyme (ACE) inhibitor (enalapril), or placebo. 18 Except for a small difference between doxazosin and chlorthalidone in their effects on SBP (chlorthalidone was more effective), the five drugs were of equivalent antihypertensive efficacy.
In the Department of Veteran Affairs study, 1292 men with a baseline DBP between 95 mm Hg and 109 mm Hg were randomized to treatment with atenolol, captopril, clonidine, diltiazem, hydrochlorothiazide, prazosin or placebo. 19 The drugs were titrated to a DBP goal of lower than 90 mm Hg. Patients who achieved this goal entered a 1-year maintenance phase, during which the DBP goal was lower than 95 mm Hg. A positive response was defined as achievement of both goals. The study found no significant difference in response rates among five of the six drugs -atenolol (51% response), clonidine (50%), hydrochlorothiazide (46%), captopril (42%), and prazosin (42%). 19 The best response was achieved in diltiazem-treated patients, of whom 59% reached both goals. Diltiazem was significantly more effective than captopril, prazosin and placebo (25%). 19 In the TOMHS, a study in which 20% of the subjects were African American, mean DBP was approximately 5 mm Hg lower with active treatment than with placebo at 48 months. 18 In the Department of Veteran Affairs study, placebo reduced DBP by an average of 5 mm Hg; active treatment by 10-14 mm Hg at 1 year. 19 Monotherapy at usual drug doses can thus be expected to reduce DBP by approxi- Journal of Human Hypertension mately 5 mm Hg when administered over a prolonged treatment period. A prolonged reduction in pressure of this magnitude has been associated with a 21% reduction in the risk of coronary heart disease, and a 34% reduction in the risk of stroke. 3 This calculation of expected risk reduction assumes that the mechanism by which BP is lowered is unimportant. Evidence is emerging, however, that this may not be the case.
Effect of inhibition of the reninangiotensin system on cardiovascular morbidity and mortality
Angiotensin-converting enzyme inhibitors are highly beneficial for the treatment of patients at high risk for cardiovascular events, including those with established atherosclerosis, left-ventricular dysfunction, postmyocardial infarction, and heart failure. In four major outcomes trials (Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS); the Survival and Ventricular Enlargement Trial (SAVE); the Studies of Left Ventricular Dysfunction (SOLVD); Heart Outcomes Prevention Evaluation (HOPE)), treatment with ACE inhibitors led to substantial reductions in cardiovascular morbidity and mortality. [20] [21] [22] [23] These benefits were realized independent of the BP status of the participants at baseline (19-24% were hypertensive in CONSENSUS compared with 42-48% in SAVE, SOLVD and HOPE).
The HOPE trial is particularly persuasive because it included a relatively broad range of high-risk patients. In this 5-year trial, 9297 patients with vascular disease or diabetes mellitus plus one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein cholesterol levels, cigarette smoking or microalbuminuria) were randomized to treatment with the ACE inhibitor, ramipril (10 mg once daily), or placebo. Patients with cardiac failure, low ejection fraction, overt nephropathy or uncontrolled hypertension were excluded. Ramipril significantly reduced the risk of stroke, myocardial infarction, or cardiovascular mortality by 32%, 20% and 26%, respectively (Table 1) . 23 The reduction in BP associated with ramipril in this trial was reported as minimal (mean reductions of 3 mm Hg in both SBP and DBP), although HOPE was not a BP trial and BPs were not monitored with the frequency and rigour customary for trials of antihypertensive treatment. The mean BPs of the two treatment groups were very similar at the end of the trial (139/76 mm Hg in the ramipril group vs 139/77 mm Hg in the placebo group). These findings suggest that inhibition of the renin-angiotensin system provides cardiovascular benefit in addition to that achieved from lowering BP. One of the major drawbacks of ACE inhibitors is their side-effect profile. ACE inhibitor-induced cough, which affected up to 18% of patients in some studies, 24 is associated with reduced compliance and, therefore, reduced antihypertensive efficacy. 16 Minimizing adverse effects of treatment is particularly important in hypertensive patients, who may be asymptomatic prior to treatment. 16 An alternative method of inhibiting the renin-angiotensin system is by blocking the angiotensin II type 1 (AT 1 ) receptor using an angiotensin II (A II) receptor blocker. In contrast to ACE inhibitors, A II receptor blockers have a side-effect profile that is similar to that of placebo. 25 These drugs may therefore be an attractive alternative to ACE inhibitors for hypertensive patients.
Angiotensin receptor blockers
Six A II receptor blockers (candesartan, eprosartan, irbesartan, losartan, telmisartan, and valsartan) are currently available for the treatment of hypertension. The antihypertensive efficacy of these agents has been reported to be similar or slightly superior to that of ACE inhibitors [26] [27] [28] [29] [30] [31] and equivalent to that of the calcium channel blocker, amlodipine. [32] [33] [34] [35] [36] Available data suggest that A II receptor blockers have a highly beneficial effect on hypertensionrelated target organ damage. It has been shown that 1 year of treatment with losartan normalizes endo- thelium-dependent relaxation, media-to-lumen ratio in arteries, and stiffness of resistance arteries in hypertensive patients, while atenolol causes a reduction in BP, but fails to improve endothelial function. 37, 38 Irbesartan, losartan, and valsartan have also been shown to reduce left ventricular mass in patients with hypertension. [39] [40] [41] Angiotensin II receptor blockers may also be effective in controlling other forms of vascular disease. Candesartan has been seen to attenuate the damaging effects of oxidized low-density lipoprotein on endothelial cells in vitro, 42 while in vivo treatment with the newest A II receptor blocker, olmesartan, results in a 40% reduction in atherosclerotic lesion area in the aorta of Watanabe heritable hyperlipidaemic (WHHL) rabbits compared with the vehicletreated control (Figure 2 ). This effect was achieved without any change in plasma cholesterol concentration. 43 Both olmesartan and losartan prevent plaque formation in a cholesterol-fed primate model of atherosclerosis. 43, 44 Olmesartan has also shown promise for the treatment of diabetic nephropathy. In the Zucker diabetic fatty rat, an animal model of type-2 diabetes, treatment with olmesartan resulted in dose-dependent reductions in urinary protein excretion that were independent of changes in BP and plasma glucose concentration. 43 
Do angiotensin receptor blockers differ in efficacy?
The first A II receptor blocker, losartan, was approved for clinical use in 1995. Since then, the US Food and Drug Administration has approved five more drugs of this class. Most head-to-head comparative trials of the efficacy of A II receptor blockers have been of newer agents against losartan, the original A II receptor blocker. [45] [46] [47] [48] When titrated to maximal dose, both irbesartan and candesartan have been shown to be more effective than losartan in reducing BP. 46, 48 In contrast, comparisons of losartan and valsartan have indicated that these agents are roughly equivalent in terms of antihypertensive efficacy. 45, 47 Olmesartan has yet to be approved for clinical use. 49 Patients with mild-to-moderate essential hypertension (n = 578) were randomized to treatment for 8 weeks. Both cuff and ambulatory BP monitoring were used to assess the patients' response.
After 8 weeks of treatment, the reduction in mean cuff DBP (the primary efficacy variable of the study) was significantly greater in patients treated with olmesartan (11.5 mm Hg) than in those who received losartan, valsartan, or irbesartan (8.2 mm Hg, 7.9 mm Hg and 9.9 mm Hg, respectively (Figure 3 ). The reduction in SBP with olmesartan was also greater than that achieved with losartan, valsartan, and irbesartan (11.3 mm Hg vs 9.5 mm Hg, 8.4 mm Hg and 11.0 mm Hg), but the differences were not statistically significant.
The results of the 24-h ambulatory BP monitoring after 8 weeks of treatment were similar to those obtained using cuff BP measurements (Figure 4 ). The reduction in mean 24-h DBP with olmesartan (8.5 mm Hg) was significantly greater than the reductions obtained with losartan and valsartan (6.2 mm Hg and 5.6 mm Hg, respectively; P р 0.05) but was not significantly different from that seen with irbesartan (7.4 mm Hg; P = 0.0867). A similar pattern was evident in the 24-h ambulatory SBP data. Olmesartan reduced mean 24-h SBP by 12.5 mm Hg after 8 weeks. This decrease was significantly greater than that achieved by losartan and valsartan (9.0 mm Hg Journal of Human Hypertension and 8.1 mm Hg, respectively) but was not significantly different from the reduction seen with irbesartan (11.3 mm Hg). As is characteristic of A II receptor blockers, all four drugs used in this study were well tolerated. 49 
Conclusions
Epidemiological research has shown that reducing BP by even a small amount can have a substantial positive impact on cardiovascular morbidity and mortality. While all classes of antihypertensive drugs are effective in lowering BP, their effectiveness in clinical practice may be limited by unfavourable adverse-effect profiles and patient non-compliance. Furthermore, there is growing evidence that drugs that inhibit the renin-angiotensin system have a greater beneficial effect on cardiovascular outcomes than can be explained by their antihypertensive effect alone. This has been widely demonstrated for ACE inhibitors and may also be true for A II receptor blockers. Olmesartan combines the advantages of vasoprotective effects independent of BP, a favourable (placebo-like) adverse-event profile, and antihypertensive efficacy superior to some of the older A II receptor blockers. Outcome trials are needed to assess the full cardiovascular benefits of olmesartan treatment.
